Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

被引：287

作者：

Miranda, Roberto N. ^{[1
]}

Aladily, Tariq N. ^{[19
]}

Prince, H. Miles ^{[20
,21
]}

Kanagal-Shamanna, Rashmi ^{[1
]}

de Jong, Daphne ^{[22
]}

Fayad, Luis E. ^{[1
]}

Amin, Mitual B. ^{[5
]}

Haideri, Nisreen ^{[6
]}

Bhagat, Govind ^{[7
,8
]}

Brooks, Glen S. ^{[9
]}

Shifrin, David A. ^{[12
]}

O'Malley, Dennis P. ^{[13
]}

Cheah, Chan Y. ^{[20
,21
]}

Bacchi, Carlos E. ^{[24
]}

Gualco, Gabriela ^{[24
]}

Li, Shiyong ^{[14
]}

Keech, John A., Jr. ^{[15
]}

Hochberg, Ephram P. ^{[10
]}

Carty, Matthew J. ^{[11
]}

Hanson, Summer E. ^{[1
]}

Mustafa, Eid ^{[3
]}

Sanchez, Steven ^{[4
]}

Manning, John T., Jr. ^{[1
]}

Xu-Monette, Zijun Y. ^{[1
]}

Miranda, Alonso R. ^{[2
]}

Fox, Patricia ^{[1
]}

Bassett, Roland L. ^{[1
]}

Castillo, Jorge J. ^{[16
]}

Beltran, Brady E. ^{[25
]}

de Boer, Jan Paul ^{[23
]}

Chakhachiro, Zaher ^{[26
]}

Ye, Dongjiu ^{[17
]}

Clark, Douglas ^{[18
]}

Young, Ken H. ^{[1
]}

Medeiros, L. Jeffrey ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Houston, Houston, TX USA

[3] Plast & Reconstruct Surg, Wichita Falls, TX USA

[4] Pathol Associates Tyler, Tyler, TX USA

[5] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA

[6] St Lukes Canc Inst, Kansas City, MO USA

[7] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA

[8] Herbert Irving Comprehens Canc Ctr, New York, NY USA

[9] Tufts Univ, Longmeadow, MA USA

[10] Massachusetts Gen Hosp, Boston, MA 02114 USA

[11] Brigham & Womens Hosp, Boston, MA 02115 USA

[12] Advocate Med Grp Plast Surg, Oak Lawn, IL USA

[13] Clarient Labs GE Healthcare, Aliso Viejo, CA USA

[14] Emory Univ Hosp, Atlanta, GA 30322 USA

[15] MultiCare Hlth Syst, MultiCare Reg Canc Ctr, Tacoma, WA USA

[16] Brown Univ, Miriam Hosp, Warren Alpert Med Sch, Providence, RI USA

[17] Bioreference Labs, Elmwood Pk, NJ USA

[18] New Mexico Canc Ctr, Albuquerque, NM USA

[19] Univ Jordan, Amman, Jordan

[20] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[21] Univ Melbourne, Melbourne, Vic, Australia

[22] Vrije Univ, Med Ctr, Amsterdam, Netherlands

[23] Netherlands Canc Inst, Amsterdam, Netherlands

[24] Consultoria Patol, Sao Paulo, Brazil

[25] Edgardo Rebagliati Martins Hosp, Lima, Peru

[26] Amer Univ Beirut, Med Ctr, Beirut, Lebanon

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 02期

关键词：

CAPSULE;

D O I：

10.1200/JCO.2013.52.7911

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clinicopathologic entity that usually presents as an effusion-associated fibrous capsule surrounding an implant. Less frequently, it presents as a mass. The natural history of this disease and long-term outcomes are unknown. Patients and Methods We reviewed the literature for all published cases of breast implant-associated ALCL from 1997 to December 2012 and contacted corresponding authors to update clinical follow-up. Results The median overall survival (OS) for 60 patients was 12 years (median follow-up, 2 years; range, 0-14 years). Capsulectomy and implant removal was performed on 56 of 60 patients (93%). Therapeutic data were available for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who did not receive chemotherapy, 12 patients opted for watchful waiting and four patients received radiation therapy alone. Thirty-nine (93%) of 42 patients with disease confined by the fibrous capsule achieved complete remission, compared with complete remission in 13 (72%) of 18 patients with a tumor mass. Patients with a breast mass had worse OS and progression-free survival (PFS; P = .052 and P = .03, respectively). The OS or PFS were similar between patients who received and did not receive chemotherapy (P = .44 and P = .28, respectively). Conclusion Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission. Proper management for these patients may be limited to capsulectomy and implant removal. Patients who present with a mass have a more aggressive clinical course that may be fatal, justifying cytotoxic chemotherapy in addition to removal of implants.

引用

页码：114 / 120

页数：7

共 30 条

[21]

Ralfkiaer E, 2008, PRIMARY CUTANEOUS CD, P300

[22] Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder [J].

Roden, Anja C. ;

Macon, William R. ;

Keeney, Gary L. ;

Myers, Jeffrey L. ;

Feldman, Andrew L. ;

Dogan, Ahmet .

MODERN PATHOLOGY, 2008, 21 (04) :455-463

[23]

Sahoo Sunati, 2003, Arch Pathol Lab Med, V127, pe115

[24] Reported complications of silicone gel breast implants: An epidemiologic review [J].

Silverman, BG ;

Brown, SL ;

Bright, RA ;

Kaczmarek, RG ;

ArrowsmithLowe, JB ;

Kessler, DA .

ANNALS OF INTERNAL MEDICINE, 1996, 124 (08) :744-756

[25] Breast implant related Anaplastic Large Cell Lymphoma presenting as late onset pen-implant effusion [J].

Smith, Trevor J. ;

Ramsaroop, Reena .

BREAST, 2012, 21 (01) :102-104

[26] Lymphomas involving the breast - A study of 106 cases comparing localized and disseminated neoplasms [J].

Talwalkar, Sameer S. ;

Miranda, Roberto N. ;

Valbuena, Jose R. ;

Routbort, Mark J. ;

Martin, Alvin W. ;

Medeiros, L. Jeffrey .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (09) :1299-1309

[27] Anaplastic Large Cell Lymphoma and Breast Implants: Five Australian Cases [J].

Taylor, Kim O. ;

Webster, Howard R. ;

Prince, H. Miles .

PLASTIC AND RECONSTRUCTIVE SURGERY, 2012, 129 (04) :610E-617E

[28]

US Food and Drug Administration, 2013, AN LARG CELL LYMPH A

[29]

US Food and Drug Administration, 2013, MED DEV COMM REP AN

[30]

Zarbo RJ, 1999, ARCH PATHOL LAB MED, V123, P133

← 1 2 3 →